Antibody response to dengue virus.

In this review, we discuss the current knowledge of the role of the antibody response against dengue virus and highlight novel insights into targets recognized by the human antibody response. We also discuss how the balance of pathological and protective antibody responses in the host critically influences clinical aspects of the disease.

[1]  Robert C. Rose,et al.  Differential Enhancement of Dengue Virus Immune Complex Infectivity Mediated by Signaling-Competent and Signaling-Incompetent Human FcγRIA (CD64) or FcγRIIA (CD32) , 2006, Journal of Virology.

[2]  M. Morales-Betoulle,et al.  Circulation of Different Lineages of Dengue Virus Type 2 in Central America, Their Evolutionary Time-Scale and Selection Pressure Analysis , 2011, PloS one.

[3]  R. Bartenschlager,et al.  Molecular aspects of Dengue virus replication. , 2008, Future microbiology.

[4]  Wiley Interscience,et al.  Elevated levels of total and dengue virus‐specific immunoglobulin E in patients with varying disease severity , 2003, Journal of medical virology.

[5]  S. Sekaran,et al.  Cytokine Expression Profile of Dengue Patients at Different Phases of Illness , 2012, PloS one.

[6]  P. Young,et al.  The flavivirus NS1 protein: molecular and structural biology, immunology, role in pathogenesis and application as a diagnostic biomarker. , 2013, Antiviral research.

[7]  T. Oliphant,et al.  Structural basis of West Nile virus neutralization by a therapeutic antibody , 2005, Nature.

[8]  J. García-Machorro,et al.  Activation of the Innate Immune Response against DENV in Normal Non-Transformed Human Fibroblasts , 2011, PLoS neglected tropical diseases.

[9]  Shui-Tein Chen,et al.  Vimentin interacts with heterogeneous nuclear ribonucleoproteins and dengue nonstructural protein 1 and is important for viral replication and release. , 2010, Molecular bioSystems.

[10]  Gregory D. Gromowski,et al.  Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes , 2007, Journal of Virology.

[11]  Paul Effler,et al.  Antibody to dengue 1 detected more than 60 years after infection. , 2007, Viral immunology.

[12]  Ralf Bartenschlager,et al.  Composition and Three-Dimensional Architecture of the Dengue Virus Replication and Assembly Sites , 2009, Cell Host & Microbe.

[13]  J. García-Cordero,et al.  Analysis of antibody response in human dengue patients from the Mexican coast using recombinant antigens. , 2008, Vector borne and zoonotic diseases.

[14]  Hoa L. Nguyen,et al.  A birth cohort study of viral infections in Vietnamese infants and children: study design, methods and characteristics of the cohort , 2013, BMC Public Health.

[15]  R. Jarman,et al.  A Prospective Nested Case-Control Study of Dengue in Infants: Rethinking and Refining the Antibody-Dependent Enhancement Dengue Hemorrhagic Fever Model , 2009, PLoS medicine.

[16]  David S. Lapointe,et al.  Dengue Virus Induces Novel Changes in Gene Expression of Human Umbilical Vein Endothelial Cells , 2003, Journal of Virology.

[17]  Cameron P. Simmons,et al.  Kinetics of Viremia and NS1 Antigenemia Are Shaped by Immune Status and Virus Serotype in Adults with Dengue , 2011, PLoS neglected tropical diseases.

[18]  S. Kalayanarooj,et al.  Virus-Induced Decline in Soluble Vascular Endothelial Growth Receptor 2 Is Associated with Plasma Leakage in Dengue Hemorrhagic Fever , 2006, Journal of Virology.

[19]  K. Boonnak,et al.  Human FcγRII Cytoplasmic Domains Differentially Influence Antibody-Mediated Dengue Virus Infection , 2013, The Journal of Immunology.

[20]  Ying Zhang,et al.  The Flavivirus Precursor Membrane-Envelope Protein Complex: Structure and Maturation , 2008, Science.

[21]  A. Rothman.  Immunology and immunopathogenesis of dengue disease. , 2003, Advances in virus research.

[22]  H. R. Henriques,et al.  Targeting the Non-structural Protein 1 from Dengue Virus to a Dendritic Cell Population Confers Protective Immunity to Lethal Virus Challenge , 2013, PLoS neglected tropical diseases.

[23]  Cameron P Simmons,et al.  Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants. , 2009, The Journal of infectious diseases.

[24]  Y. Modis,et al.  A ligand-binding pocket in the dengue virus envelope glycoprotein , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. García-Machorro,et al.  DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the Dengue virus in mice , 2013, Human vaccines & immunotherapeutics.

[26]  Yee‐Shin Lin,et al.  Autoimmune pathogenesis in dengue virus infection. , 2006, Viral immunology.

[27]  M. Diamond,et al.  Lethal Antibody Enhancement of Dengue Disease in Mice Is Prevented by Fc Modification , 2010, PLoS pathogens.

[28]  Wei Zhang,et al.  Structure of the Immature Dengue Virus at Low pH Primes Proteolytic Maturation , 2008, Science.

[29]  J. Crowe,et al.  Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. , 2013, The Journal of infectious diseases.

[30]  S. Lok,et al.  A Human PrM Antibody That Recognizes a Novel Cryptic Epitope on Dengue E Glycoprotein , 2012, PloS one.

[31]  A. Sabin.  Research on dengue during World War II. , 1952, The American journal of tropical medicine and hygiene.

[32]  C. Rice,et al.  Molecular biology of the flaviviruses. , 1987, Microbiological sciences.

[33]  Scott D Boyd,et al.  Convergent antibody signatures in human dengue. , 2013, Cell host & microbe.

[34]  Andreas Radbruch,et al.  Survival of long-lived plasma cells is independent of antigen. , 1998, International immunology.

[35]  Cameron P Simmons,et al.  The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. , 2010, Cell host & microbe.

[36]  G. Perng,et al.  Dengue virus-induced hemorrhage in a nonhuman primate model. , 2010, Blood.

[37]  K. Stiasny,et al.  Flaviviruses and their antigenic structure. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[38]  A. Nisalak,et al.  Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. , 2005, The Journal of infectious diseases.

[39]  J. Lepault,et al.  Dengue Virus Type 1 Nonstructural Glycoprotein NS1 Is Secreted from Mammalian Cells as a Soluble Hexamer in a Glycosylation-Dependent Fashion , 1999, Journal of Virology.

[40]  J. Roehrig,et al.  Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. , 1998, Virology.

[41]  A. Nisalak,et al.  Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. , 1989, The American journal of tropical medicine and hygiene.

[42]  G. Perng,et al.  Can non-human primates serve as models for investigating dengue disease pathogenesis? , 2013, Front. Microbiol..

[43]  R. D. del Ángel,et al.  The Cytokine Response of U937-Derived Macrophages Infected through Antibody-Dependent Enhancement of Dengue Virus Disrupts Cell Apical-Junction Complexes and Increases Vascular Permeability , 2013, Journal of Virology.

[44]  Fernando A Bozza,et al.  Multiplex cytokine profile from dengue patients: MIP-1beta and IFN-gamma as predictive factors for severity , 2008, BMC infectious diseases.

[45]  Antonio Lanzavecchia,et al.  Broadly neutralizing antiviral antibodies. , 2013, Annual review of immunology.

[46]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[47]  G. Nybakken,et al.  Antibodies against West Nile Virus Nonstructural Protein NS1 Prevent Lethal Infection through Fc γ Receptor-Dependent and -Independent Mechanisms , 2006, Journal of Virology.

[48]  Alan L Rothman,et al.  Dengue: defining protective versus pathologic immunity. , 2004, The Journal of clinical investigation.

[49]  A. Tripathy,et al.  Clinical Findings and Pro-Inflammatory Cytokines in Dengue Patients in Western India: A Facility-Based Study , 2010, PloS one.

[50]  S. Kalayanarooj,et al.  B-cell responses during primary and secondary dengue virus infections in humans. , 2011, The Journal of infectious diseases.

[51]  R. Baric,et al.  Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity , 2014, Proceedings of the National Academy of Sciences.

[52]  F. Ennis,et al.  Gamma interferon augments Fc gamma receptor-mediated dengue virus infection of human monocytic cells , 1988, Journal of virology.

[53]  S. Kalayanarooj,et al.  Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. , 2010, The Journal of infectious diseases.

[54]  C. Mandl,et al.  Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. , 2003, The Journal of general virology.

[55]  B. Pulendran,et al.  Rapid and Massive Virus-Specific Plasmablast Responses during Acute Dengue Virus Infection in Humans , 2012, Journal of Virology.

[56]  Re-evaluation of the pathogenic roles of nonstructural protein 1 and its antibodies during dengue virus infection , 2013, Journal of Biomedical Science.

[57]  Charles M. Rice,et al.  Architects of assembly: roles of Flaviviridae non-structural proteins in virion morphogenesis , 2008, Nature Reviews Microbiology.

[58]  R. Steinman,et al.  Targeting of envelope domain III protein of DENV type 2 to DEC-205 receptor elicits neutralizing antibodies in mice. , 2013, Vaccine.

[59]  Douglas T. Golenbock,et al.  Flavivirus Activation of Plasmacytoid Dendritic Cells Delineates Key Elements of TLR7 Signaling beyond Endosomal Recognition1 , 2006, The Journal of Immunology.

[60]  Wei Zhang,et al.  Structure of Dengue Virus Implications for Flavivirus Organization, Maturation, and Fusion , 2002, Cell.

[61]  J. Low,et al.  Dengue Virus Activates Polyreactive, Natural IgG B Cells after Primary and Secondary Infection , 2011, PloS one.

[62]  Yee‐Shin Lin,et al.  Deletion of the C-Terminal Region of Dengue Virus Nonstructural Protein 1 (NS1) Abolishes Anti-NS1-Mediated Platelet Dysfunction and Bleeding Tendency1 , 2009, The Journal of Immunology.

[63]  M. Beltramello,et al.  Human antibodies against dengue enhance dengue viral infectivity without suppressing type I interferon secretion in primary human monocytes. , 2011, Virology.

[64]  J. Connolly,et al.  Leukocyte immunoglobulin-like receptor B1 is critical for antibody-dependent dengue , 2014, Proceedings of the National Academy of Sciences.

[65]  A. Haenni,et al.  Recent developments in understanding dengue virus replication. , 2010, Advances in virus research.

[66]  Gregory D. Gromowski,et al.  Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. , 2007, Virology.

[67]  P. Puthavathana,et al.  Role of Dendritic Cells in Antibody-Dependent Enhancement of Dengue Virus Infection , 2008, Journal of Virology.

[68]  A. Nisalak,et al.  Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. , 1988, The American journal of tropical medicine and hygiene.

[69]  K. Stiasny,et al.  Structure of a flavivirus envelope glycoprotein in its low‐pH‐induced membrane fusion conformation , 2004, The EMBO journal.

[70]  A. Helenius,et al.  Folding and Dimerization of Tick-Borne Encephalitis Virus Envelope Proteins prM and E in the Endoplasmic Reticulum , 2002, Journal of Virology.

[71]  K. Boonnak,et al.  Cell Type Specificity and Host Genetic Polymorphisms Influence Antibody-Dependent Enhancement of Dengue Virus Infection , 2010, Journal of Virology.

[72]  F. Ennis,et al.  HUMAN IgG FC RECEPTOR I 1 MEDIATES ANTIBODY-DEPENDENT ENHANCEMENT OF DENGUE VIRUS INFECTION ' , 2001 .

[73]  Juan Wang,et al.  Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM/E and NS1: their immunity and protective efficacy in mice. , 2013, Molecular immunology.

[74]  A. Nisalak,et al.  Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. , 2000, The Journal of infectious diseases.

[75]  J. Schlesinger,et al.  Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. , 1988, The Journal of general virology.

[76]  N. Wauquier,et al.  Acute dengue virus 2 infection in Gabonese patients is associated with an early innate immune response, including strong interferon alpha production , 2010, BMC infectious diseases.

[77]  I. Kurane,et al.  Detection of higher levels of dengue viremia using FcγR-expressing BHK-21 cells than FcγR-negative cells in secondary infection but not in primary infection. , 2011, The Journal of infectious diseases.

[78]  Prida Malasit,et al.  Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans , 2010, Science.

[79]  K. Fink,et al.  Plasmablasts Generated during Repeated Dengue Infection Are Virus Glycoprotein–Specific and Bind to Multiple Virus Serotypes , 2012, The Journal of Immunology.

[80]  S. Halstead,et al.  Observations related to the pathogenesis of dengue hemorrhagic fever. II. Antigenic and biologic properties of dengue viruses and their association with disease response in the host. , 1970, The Yale journal of biology and medicine.

[81]  S. Halstead,et al.  Antibody-enhanced dengue virus infection in primate leukocytes , 1977, Nature.

[82]  Ya-jun Guo,et al.  A Broadly Flavivirus Cross-Neutralizing Monoclonal Antibody that Recognizes a Novel Epitope within the Fusion Loop of E Protein , 2011, PloS one.

[83]  A. Durbin,et al.  Next-Generation Dengue Vaccines: Novel Strategies Currently Under Development , 2011, Viruses.

[84]  Y. Seo,et al.  Type I Interferon Modulates the Battle of Host Immune System Against Viruses , 2010, Advances in Applied Microbiology.

[85]  S. Halstead,et al.  Neutralization and antibody-dependent enhancement of dengue viruses. , 2003, Advances in virus research.

[86]  M. Guzmán,et al.  Long-term memory cellular immune response to dengue virus after a natural primary infection. , 2002, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[87]  R. Rico-Hesse,et al.  Dengue Virus Tropism in Humanized Mice Recapitulates Human Dengue Fever , 2011, PloS one.

[88]  J. Smit,et al.  Immature Dengue Virus: A Veiled Pathogen? , 2010, PLoS pathogens.

[89]  J. Crowe,et al.  Persistence of Circulating Memory B Cell Clones with Potential for Dengue Virus Disease Enhancement for Decades following Infection , 2011, Journal of Virology.

[90]  T. Myint,et al.  Changes in levels of anti‐dengue virus IgG subclasses in patients with disease of varying severity , 1993, Journal of medical virology.